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http://dxObjective: Therapeutic safety and efficacy are the basic prerequisites for clinical gene therapy. We investigated
the effect of high-dose molecular cardiac surgery with recirculating delivery (MCARD)-mediated adeno-
associated virus 9 (AAV9)/sarcoplasmic reticulum Ca2þ adenosine triphosphatase (SERCA2a) gene delivery
on clinical parameters, oxidative stress, humoral and cellular immune responses, and cardiac remodeling.
Methods: Ischemic cardiomyopathy was generated in a sheep model. The sheep were assigned to 1 of 2 groups:
control (n ¼ 10) and study (MCARD, n¼ 6). The control group underwent no intervention and the study group
received 1014 genome copies of AAV9/SERCA2a 4 weeks after infarction.
Results:Our ischemic model produced reliable infarcts leading to heart failure. The baseline ejection fraction in
the MCARD group was 57.6% 1.6% versus 61.2% 1.9% in the control group (P>.05). At 12 weeks after
infarction, the MCARD group had superior left ventricular function compared with the control group: stroke
volume index, 46.6  1.8 versus 35.8  2.5 mL/m2 (P< .05); ejection fraction, 46.2%  1.9% versus
38.7%  2.5% (P<.05); and left ventricular end-systolic and end-diastolic dimensions, 41.3  1.7 versus
48.2  1.4 mm and 51.2  1.5 versus 57.6  1.7 mm, respectively (P<.05). The markers of oxidative stress
were significantly reduced in the infarct zone in the MCARD group. No positive T-cell–mediated immune
response was seen in the MCARD group at any point. Myocyte hypertrophy was also significantly attenuated
in the MCARD group compared with the control group.
Conclusions: Cardiac overexpression of the SERCA2a gene by way of MCARD is a safe therapeutic
intervention. It significantly improves left ventricular function, decreases markers of oxidative stress, abrogates
myocyte hypertrophy, arrests remodeling, and does not induce a T-cell–mediated immune response. (J Thorac
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SHeart failure (HF) is a major public health problem,
affecting>23 million people worldwide. In recent decades,
improvements have occurred in myocardial revasculariza-
tion and medical therapies, reducing 5-year mortality;
however, the number of patients developing HF has steadily
increased.1 One explanation for these phenomena is that
current surgical and therapeutic approaches are palliative
and do not address the molecular pathogenesis of HF.
Delivery of recombinant DNA to cardiac myocytes in situ
for correction of genetically acquired transformations or
by overexpression of critical signaling components that
have been downregulated is an attractive proposition. It
has become clear, however that gene therapy is a complex
process in which tissue targeting, route of delivery, cellular
trafficking, regulation of gene expression, biologic activity,
dose of the therapeutic transgene, and many other factors
must be considered. In our view, before the advent of molec-
ular cardiac surgery with recirculating delivery (MCARD),
systems allowing for gene delivery to most myocytes in situ
did not exist. Thus, the results of the Calcium Upregulationdiovascular Surgery c Volume 148, Number 3 1065
Abbreviations and Acronyms
AAV ¼ adeno-associated virus
HF ¼ heart failure
LV ¼ left ventricular
MCARD ¼ molecular cardiac surgery with
recirculating delivery
MRI ¼ magnetic resonance imaging
NAb ¼ neutralizing antibody
ROS ¼ reactive oxygen species
SERCA2a ¼ sarcoplasmic reticulum Ca2þ
adenosine triphosphatase
TOAC ¼ total antioxidant capacity
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Sby Percutaneous Administration of Gene Therapy in Car-
diac Disease trial using an inefficient intracoronary delivery
route showed no demonstrable significant improvement in
left ventricular (LV) function in patients in any group, using
doses up to and including 1013 genome copies of adeno-
associated virus (AAV) 1 encoding sarcoplasmic reticulum
Ca2þ adenosine triphosphatase (SERCA2a).2 Preclinical
data using the same dose of AAV1/SERCA2a and the
same delivery approach resulted in detectable gene expres-
sion in 0% (3 of 6) and<1% (3 of 6) myocytes in the ovine
heart.3 Using simple antegrade intracoronary delivery,
>99% of the vector promptly disappears into the systemic
circulation.4 Thus, we believe that gene delivery is the
rate-limiting barrier to effective gene therapy for HF.
We, and others, have shown that gene transfer with
SERCA2a improves ventricular function in an experimental
model of HF.5,6 However, SERCA2a overexpression
enhances the heart’s energetic state and might potentially
increase the probability of ventricular arrhythmias.7,8
Therefore, a careful analysis of the adverse cardiac effects
of SERCA2a, especially in high doses, using an efficient
delivery system such as MCARD, must be completed
before clinical translation.
For our study, we chose AAV, currently among the most
frequently used viral vectors for gene therapy. The AAV1
vector was used in a phase I/II HF gene therapy clinical
trial.2 We have also used AAV1 and AAV6 in previous
studies.5,9 To achieve prolonged cardiotropic transgene
expression that will be stable for 1 year, it was shown
that AAV9 might be superior to other serotypes.10,11
Nonetheless, AAV vectors have been shown to evoke
cellular and humoral immune responses, with T cells
activated toward the expressed transgene and vector
capsid proteins.12 Therefore, we hypothesized that
combining a high transgene dose with a highly efficient,
cardiac-specific delivery method, such as MCARD, would
simultaneously enhance efficacy and limit potentially
dangerous systemic exposure, abrogating an untoward
immune response.1066 The Journal of Thoracic and Cardiovascular SurIn the present study, we investigated the effect
of MCARD-mediated high-dose AAV9/SERCA2a on LV
function, therapeutic safety of multiple organs, oxidative
stress, cellular and humoral immune responses, and cardiac
remodeling in a relevant preclinical model of HF.
METHODS
Animals and Study Design
All the sheep received humane care in compliance with the National
Institutes of Health regulations, and the Carolinas Medical Center approved
the protocol. An ischemic cardiomyopathy model was generated in
16 Dorsett male sheep weighing 49.7  2.5 kg. The sheep were then
randomly divided into 2 groups: a control group (n ¼ 10) and study
group (n ¼ 6). After 4 weeks, the sheep in the study group underwent
cardiopulmonary bypass, including MCARD-AAV9/SERCA2a gene
transfer. Hemodynamic and energetic studies were conducted at baseline
and 3 and 12 weeks after infarction in both groups. The sheep were then hu-
manelykilled, and the tissuewas harvested and stored for additional analysis.
Animal Model of HF
The proximal portion of the first and second branches of the circumflex
artery were identified and surgically ligated as previously described.5
MCARD and Gene Delivery
The surgical details of the MCARD procedure have been previously
described.5,9 In brief, after sternotomy, cardiopulmonary bypass was
established by way of bicaval and right carotid artery cannulation. The aorta
was cross-clamped. Cold (4C) del Nido cardioplegia solution was delivered
antegrade. Closed-loop cardiac isolated circuit flow was initiated. The virus
solution, consisting of 1014 genome copies of AAV9/SERCA2a, was injected
into the retrograde coronary sinus catheter and recirculated for 20minutes.The
circuitwas thenflushed towash out residual vector.After crossclamp removal,
the sheep were weaned from cardiopulmonary bypass, and the chest was
closed. All the sheep received critical cardiac postoperative care.
Recombinant AAV9/SERCA2a Vector Construction
Vector production, harvest, purification, and testing were done from cell
lysates by the Penn Vector Core (available at: http://www.med.upenn.edu/
gtp/vectorcore/). The recombinant AAV9.SERCA2a vector used in the
present study contains an AAV serotype-9 viral capsid and a single
strand: 4.5-kb DNA containing the human SERCA2a cDNA driven by
a cytomegalovirus immediate-early promoter/enhancer, a hybrid intron,
and a bovine growth hormone polyadenylation signal.
Cardiac Parameter Measurements
Six-lead electrocardiography (MAC 1600; Hewlett-Packard, Palo Alto,
Calif) was performed in all resting sheep at baseline, immediately after
infarction, and at 12 weeks, with analysis of the waveform components.
Transthoracic and transepicardial echocardiography with color flow
Doppler was performed using a 7-MHz transducer (Acuson; Siemens
Healthcare, Mountain View, Calif). Magnetic resonance imaging (MRI;
Signa LX, GEHealthcare, Buckinghamshire, United Kingdom) acquisition
and analysis of cardiac hemodynamics were generated for each sheep at the
selected points. Evaluation of the cardiac cycles was obtained using cardiac
MRI software (available at: http://www.segment.heiberg.se).
Polymerase Chain Reaction Detection of AAV Vector
Genome
RNA and DNA were isolated from specimens using the Chemagen
(Perkin-Elmer, Baesweiler, Germany)MSM1 kits to set up separate reverse
transcriptase-polymerase chain reaction (PCR) and quantitative PCRgery c September 2014
FIGURE 1. A, Quantitative polymerase chain reaction of sarcoplasmic
reticulum Ca2þ adenosine triphosphatase (SERCA2a) biodistribution in
heart and liver tissue (genome copies/100 ng DNA). B, Relative expression
by reverse transcriptase-quantitative polymerase chain reaction of
SERCA2a/glyceraldehyde 3-phosphate dehydrogenase in heart and liver
tissue.Gray columns, molecular cardiac surgery with recirculating delivery
adeno-associated virus 9/SERCA2a group; black columns, control group.
*P ¼ .05 for differences between groups; zP<.05 for differences within
groups. AAV, Adeno-associated virus; LV, left ventricular; mRNA,
messenger RNA.
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examine the expression of SERCA2a, customized kits designed by
Abiomed Systems (Abiomed, Inc, Danvers, Mass) generated the SERCA2a
primers. The level of ovine glyceraldehyde 3-phosphate dehydrogenase
RNA was used to calculate the normalized expression using the DDCt
method for the reverse transcriptase-PCR values. Absolute genomic copies
of SERCA2a DNAwere quantified using the standard normal curve.
Histologic and Electron Microscopic Assessment of
Mitochondrial Abundance and Fractional Volume
The LV sections were stained with hematoxylin and eosin. Each field
was scanned using a computer-generated microscale and analyzed blindly
using 9 to 11 randomly selected tissue sections from each of the hearts
using image analysis software. For mitochondrial assessment, the samples
were analyzed using a CM 10 transmission electron microscope (Philips,
Amsterdam, The Netherlands). The images were captured using a digital
camera system. The mitochondrial abundance per unit area and fractional
volume of mitochondria were estimated using the unbiased morphometric
stereologic approach, as previously described.13
Oxidative Markers (Malondialdehyde,
4-Hydroxynonenal)
LV tissue was homogenized and centrifuged (Fisher Scientific,
ThermoFisher Scientific, Atlanta, Ga). The protein concentration was
measured using a protein assay kit according to the manufacturer’s protocol
(Bio-Rad Laboratories, Inc, Hercules, Calif). Protein conjugates of
malondialdehyde and 4-hydroxynonenal were measured using enzyme
immunoassays (Cell Biolabs, Inc, San Diego, Calif).
Total Antioxidant Capacity
The total antioxidant capacity (TAOC) was measured in LV samples
using a colorimetric microplate assay for total antioxidant power (Oxford
Biomedical Research, Rochester Hills, Mich). TAOC was expressed in
Cu2þ-reducing equivalents against a uric acid standard and normalized
for the protein content of the sample.
T-Cell–Mediated Response (Interferon-g Enzyme-
Linked ImmunoSpot Assay)
Interferon-g Enzyme-Linked ImmunoSpot assays (Mabtech, Inc,
Cincinnati, Ohio) were performed according to a previously described
protocol.14 Peptide-specific cells were represented as spot-forming cells
per 106 cells and were calculated by subtracting the spot numbers.
AAV9 Neutralizing Antibody Assay
Neutralizing antibody (NAb) assays were performed by incubating the
serotype 9 of AAV.CMV.LacZ with twofold dilutions of heat-inactivated
sheep serum and determining the b-galactosidase expression in Huh7 cells.
The limit of detection for the assay is 1:5 serumdilution.AAV9-specific total
NAb titersweredetermined usingan enzyme-linked immunosorbent assay.14
Statistical Analysis
All data are presented as the average  standard error of the mean.
The Kolmogorov-Smirnov test for normality was applied to each data
set. Single analysis of variance was performed across time (eg, baseline,
3 weeks, 12 weeks) for each parameter. Next, unpaired t tests were used
to assess the differences between any 2 points or differences at the same
time between the 2 groups (eg, study vs control).
RESULTS
Model of Ovine Postischemic HF and Operative
Results
All the sheep in both groups sustained a large trans-
mural posterolateral infarct with moderate to severe LVThe Journal of Thoracic and Cardysfunction. In the study group (MCARD-AAV9/
SERCA2a), all sheep survived without incident and
were humanely killed at 12 weeks after infarction. The
average cardiopulmonary bypass and crossclamp time was
143  6 and 77  5 minutes, respectively. In 1 case in the
control group, the sheep developed refractory ventricular
fibrillation after coronary ligation and was excluded from
the study. The LV infarct size was similar between the con-
trol and study groups (19.4%  2.1% vs 20.6%  1.6%;
P>.05).
Cardiac and Liver Expression After High-Dose
AAV9/SERCA2a Gene Transfer
The cardiac tissue delivery of SERCA2a genome copies
in the MCARD-AAV9/SERCA2a group was significantly
increased in the LV anterior and lateral walls compared
with the liver and heart tissue from the control group
(P< .05 for both; Figure 1, A). In contrast, no difference
was seen in the SERCA2a genome copies in the liver
between the 2 groups. The same trends were observed using
reverse transcriptase-quantitative PCR to assess the relative
expression of SERCA2a in the cardiac samples in the study
group compared with the control group (Figure 1, B).
Cardiac Function and LV Remodeling
Global cardiac function was not significantly different
between the 2 groups on the baseline MRI scan. Creation
of myocardial infarction resulted in deterioration of heartdiovascular Surgery c Volume 148, Number 3 1067
FIGURE 2. Baseline and 3- and 12-weeks postinfarction values for (A) left ventricular (LV) ejection fraction (%), (B) stroke volume index (mL/m2),
(C) end-systolic diameter (mm), (D) end-diastolic diameter (mm), (E) left ventricular wall thickness (mm), and (F) left ventricular fractional wall
thickening (%). Gray columns, molecular cardiac surgery with recirculating delivery of adeno-associated virus 9/sarcoplasmic reticulum Ca2þ adenosine
triphosphatase group; black columns, control group. *P<.05 for differences between groups.
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and control groups, a decrease in ejection fraction by
22.6%  5.5% and 24.7%  3.4% and an increase in
end-diastolic volume by 22.7%  6.0% and 22.0% 
6.7% and end-systolic volume by 57.8%  6.2% and
71.0%  11.4%, respectively, was seen (P>.05 for all).
At 12 weeks, the MCARD-AAV9/SERCA2a–treated HF
sheep showed significant improvement in systolic and
diastolic LV function compared with the control group
(ejection fraction, 46.2%  1.9% vs 38.7%  2.5%;
stroke volume index, 46.6  1.8 vs 35.8  2.5 mL/m2;
end-systolic diameter, 41.3  1.7 vs 48.2  1.4 mm;
end-systolic volume, 66.7  5.0 vs 80.3  5.1 mL;
end-diastolic diameter, 51.2  1.5 vs 57.6  1.7 mm;
P < .05 for all). Analysis of LV remodeling revealed
significantly decreased LV end-systolic volumes and end-
diastolic dimensions after gene therapy (Figure 2, A-D).
In line with improvements in global cardiac function, the
assessment of regional contractility demonstrated that the
LV wall thickness in the MCARD group was relatively
stable and remained approximately 11 mm across the
follow-up points. This finding suggested a high likelihood
of recovery of regional contractile function after myocardial
infarction.15 In contrast, in the control group, the LV1068 The Journal of Thoracic and Cardiovascular Surthickness had decreased significantly after 12 weeks and
the chances of recovery were very low (Figure 2, E).
Also, LV fractional systolic wall thickening was signifi-
cantly greater in the MCARD-AAV9/SERCA2a group at
12 weeks than in the control group (48.3%  2.9% vs
17.6%  3.7%, P<.01; Figure 2, F).
Myocardial Hypertrophy, Mitochondrial
Abundance, and Fractional Volume
The cross-sectional areas of myocytes from the MCARD
sheep were significantly smaller than those in the control
sheep (98  0.7 vs 89  0.7 mm2; P< .01; Figure 3,
A-C), indicating significantly less myocyte hypertrophy.
The mitochondria in the control group occupied a smaller
fraction of the total tissue volume than in the MCARD
group (22.0%  1.7 vs 30.2%  1.9%; P<.05) and also
exhibited a lower mitochondrial density (0.16  0.01 vs
0.45  0.04 per mm2; P < .05). These findings were
consistent with an increase in mitochondrial swelling in
the control group (Figure 3, D-G).
Oxidative Stress and TAOC Markers
In the MCARD group, malondialdehyde and
4-hydroxynonenal conjugate concentrationswere significantlygery c September 2014
FIGURE 3. Morphometric analysis ofmyocytes andmitochondria. Hematoxylin and eosin-stained infarct border zone tissue cross-section (scale bar¼ 40mm)
from (A) the control group and (B) molecular cardiac surgery with recirculating delivery of adeno-associated virus 9/sarcoplasmic reticulum Ca2þ adenosine
triphosphatase group (MCARD-AAV9/SERCA2a). C, Average cross-sectional cardiac myocyte area in infarct border zone (mm2). Transmission electron
microscopy of infarct border zone tissue (scale bar ¼ 1 mm) from (D) control group (arrows indicate mitochondrial swelling) and (E) MCARD-AAV9/
SERCA2agroup (arrows indicatenormal-appearingmitochondria).Average stereologic estimates of (F)mitochondrial fractional volume (%) and (G)mitochon-
drial density (per mm2). Gray columns, MCARD-AAV9/SERCA2a group; black columns, control group. *P<.05 for differences between groups.
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remote zone (malondialdehyde, 0.00  0.00 vs 1.51  0.24
pmol/mg protein; 4-hydroxynonenal, 1.04  0.41 vs
8.22  0.96 mg/mg protein; P<.05). In contrast, the control
group showed no significant differences between these zones
(Figure 4,A andB).We did not find any significant differences
in antioxidant capacity (TAOC) between the 2 groups orwithin
the groups (P>.05).
Blood Work and Electrocardiographic Safety Profile
Complete blood counts and chemistry analysis for
comprehensive metabolic evaluation of all major organs
and physiologic systems were conducted preoperatively
and postoperatively at 12 weeks after infarction. All data
are summarized in Table E1. The mean post–MCARD-
AAV9/SERCA2a serologic values at 12 weeks were
generally within normal limits. In particular, the levels ofThe Journal of Thoracic and Carcreatinine, blood urea nitrogen, alanine aminotransferase,
alkaline phosphatase, and total bilirubin remained well
within the reference ranges.
The electrocardiographic assessment at 12 weeks after
infarct showed that theQRS intervalwas significantly length-
ened at 12 weeks in the control group. In contrast, the
MCARD group had maintained baseline levels (60  15 vs
34 4 ms; P<.05). The PQ interval, QT interval, and heart
rate were unaffected by treatment. As expected, the ST seg-
ments were significantly elevated after infarct creation and
at 12 weeks remained slightly perturbed (Table E2). No ar-
rhythmias were detected in either group.
Immune Response to AAV9 and SERCA2a Transgene
TheT-cell immune response toAAV9andSERCA2a trans-
gene was evaluated using the interferon-g Enzyme-Linked
ImmunoSpot assay at selected follow-up points. None ofdiovascular Surgery c Volume 148, Number 3 1069
FIGURE 4. Oxidative markers in infarct and remote tissue
zones. A, Malondialdehyde (MDA) concentration (pmol/mg protein). B,
4-Hydroxynonenal–protein conjugates in hydroxynonenal–bovine serum
albumin equivalents (mg/mg protein).Gray columns, molecular cardiac surgery
with recirculating delivery of adeno-associated virus 9/sarcoplasmic reticulum
Ca2þ adenosine triphosphatase group; black columns, control group. *P<.05
for differences within groups. BSAeq, Body surface area equivalents; HNE,
4-hydrooxynonenal conjugate.
FIGURE 5. Time course of transgene-specific T-cell responses to pools of
adeno-associated virus 9 (AAV9) capsid peptides and pools of sarcoplasmic
reticulum Ca2þ adenosine triphosphatase (SERCA2a) transgene in
peripheral blood mononuclear cells (PBMCs) after administration of
AAV9/SERCA2a. SFU, Number of interferon-g spot-forming units in
Enzyme-Linked ImmunoSpot assay of left ventricular tissue samples;
No stim, negative control; PMAþION, positive control. Red line indicates
positive result threshold; A, B, C, and D each refer to a specific sheep in the
molecular cardiac surgery with recirculating delivery-AAV9/SERCA2a
group.
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T-cell–mediated immune response to AAV9 capsid or
human SERCA2a at any of the tested points in all sheep
(Figure 5).
The presence of pre-existing antibodies is an important
barrier to gene therapy, because it strongly affects transgene
expression. Therefore, the sheep were prescreened for the
presence of NAbs against the administered AAV9. The
AAV9 NAb levels at baseline in sheep who had not
previously received AAV9 vector were nondetectable using
an enzyme-linked immunosorbent assay; thus, all showed
corresponding titers <1:5. The 6 MCARD sheep that
received rAAV9 vector had increases in the NAb titers of
>1 in 120 against AAV9 at 9 and 12 weeks after the
MCARD procedure.
DISCUSSION
The consistent coronary arterial anatomy in sheep,
similar to that of humans, and a lack of collateral vessels
provides substantial advantages for creation of a clinically
relevant ischemic cardiomyopathy model with a predictable
myocardial infarct size in this species.16 This physiologi-
cally appropriate large animal model, involving ligation
of the circumflex artery’s first 2 branches, is accompanied
by almost 0% mortality and is highly suitable for
demonstrating ventricular remodeling after gene therapy.1070 The Journal of Thoracic and Cardiovascular SurIn the present study, we confirmed our previous
efficacy claims by showing that MCARD delivery of
AAV9/SERCA2a results in robust expression in the lateral
and anterior walls of the left ventricle with an almost
100-fold greater level of expression than in the liver. MRI
analysis showed the favorable effects of SERCA2a
expression through improved global and regional cardiac
mechanics and the substantial arrest of remodeling.
Postinfarction remodeling is usually divided into early
and late phases. The early phase involves expansion of the
infarct zone. Late remodeling is caused in part by failure
to normalize the increases in wall stress and is associated
with time-dependent progressive LV dilatation, distortion
of the ventricular shape, deterioration of contractile
function, and myocyte hypertrophy. Alterations to myocyte
architecture will initially stabilize the distending forces and
prevent additional ventricular deformation but are
associated with increased energy consumption. Studies
have indicated that in the healthy heart, the mitochondrial
function and structure will match the maximal energy
demand. However, in a failing myocardium, the energy
and demand are mismatched.17 As expected, we found,
through histologic analysis, that a loss of mitochondrial
density occurred in the control group but that MCARD/
SERCA2a treatment prevented mitochondrial loss, thereby
preserving the high aerobic capacity of the muscle tissue.
The decrease in mitochondrial density was proportionally
greater than the decrease in fractional volume, suggesting
evidence of maladaptive mitochondrial swelling in the
control group. Morphometric analysis of the electron
microscopic images in our study showed that the number
of mitochondria per myocyte decreased and the volume of
individual mitochondria increased in the controls but
not in the treatment group. A reduction in the number ofgery c September 2014
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pro-apoptotic pathways in HF, and the relative increase in
mitochondrial volume (swelling) is a failed compensatory
response.
It is accepted that oxidative stress is caused by an
imbalance between the generation of reactive oxygen
species (ROS) and antioxidant defense mechanisms and is
an important regulator of cardiac remodeling.18 In contrast
to the direct actions on cellular injury, ROS also play an
important role in cell protection by activation and
expression of antioxidant enzymes.19 Among the biologic
processes, the level of lipid peroxidation is widely used as
a biomarker of oxidative stress because the lipids are
most susceptible to ROS. Myocytes can accumulate ROS
as a result of either increased numbers of total mitochondria
producing ROS or the production of higher levels of ROS by
damaged mitochondria.20 This can lead to the deterioration
of cellular function and viability.
Natural AAV infections or AAV gene therapy can cause
the development of AAV NAbs in animal species and
humans. Pre-existing antibodies can modulate the efficacy
of gene therapy by blocking vector transduction or
redirecting distribution of the AAV vectors.21 One of the
most important aspects of the development of AAV for
clinical gene therapy is the effect of the host humoral
immune response against its capsid. No pre-existing
AAV9 antibodies were found in any sheep in either group;
however, moderate titers were found in the treatment group
after gene therapy. One strategy to overcome AAV NAbs in
AAV-mediated gene therapy includes immunosuppression.
It was demonstrated in a dog model that after LV
intramyocardial injection of low-dose 1011 genome copies
of AAV6/SERCA2a, all the dogs developed positive
AAV-NAb titers>1 in 120. Immunosuppression beginning
4 weeks after AAV injection reduced the NAb titers to
baseline levels.22 However, our finding of positive NAb
titers 9 to 12 weeks after gene delivery was not unexpected
and would will not affect efficacy, given that this was
single-dose therapy with no need for re-administration.
The immune response with activation of T cells directed
against the viral capsid constitutes an important safety
concern in the use of AAV vectors. This response is dose
dependent, and delivery of 1012 of 1013 viral genomes
(less than in our study) was associated with specific T-cells
directed against the vector capsid.23 Also, it is thought that
capsid-directed T-cell–mediated cellular destruction is
implicated in the observed toxicity in the high-dose group
in the AAV2 clinical trial for the treatment of hemophilia.24
In our study, we found no positive T-cell immune
response in any sheep at any measurement point. This
protective effect of MCARD likely resulted from the
closed-loop recirculation technique used to deliver the
vector in a highly organ-specific fashion, minimizing the
exposure of antigen-presenting cells to capsid antigens, anThe Journal of Thoracic and Carimportant and unique safety feature of the MCARD
delivery platform.
The results of the present study have demonstrated that
MCARD delivery of a high-dose of AAV9/SERCA2a is
safe and efficacious, with no toxic effects on the major
organ systems, no T-cell–mediated immune response, no
increase in the prevalence of arrhythmias, decreased
myocardial hypertrophy, and improved mitochondrial ultra-
structure, density, and function. Finally, MCARD-mediated
delivery of AAV9 expressing SERCA2a led to markedly
improved global LV function and significantly arrested
maladaptive ventricular remodeling.Study Limitations
The present study used a relatively small number of sheep
owing to the high cost and time demands of the study. A
period of follow-up>12 weeks would be desirable. We
did not incorporate a control group with intracoronary
delivery or an MCARD-null vector and other AAV
serotypes because of the high time and material costs.
Furthermore, studies using AAV1 and AAV6 have been
previously published,5 and the inefficiency of intracoronary
delivery—resulting in sequestration of >99% of the
injected vector in the liver—is well documented.3,4
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Discussion
Dr Todd K. Rosengart (Houston, Tex). Congratulations,
Dr Bridges, again, on very nice work and thank you for allowing
me to review your report in advance.
As you rightly note, and I would reiterate, there is a lack of
appreciation that many experimental and clinical cardiac gene
therapy trials have been encumbered by inadequate substrate
delivery, just as we have heard in the earlier presentations, and
again we applaud you for your diligent effort in pursuing this.1072 The Journal of Thoracic and Cardiovascular SurThe MCARD technique, I think, remains limited in the sense
that you do need cardiopulmonary bypass. Also, I am sure you
have looked very diligently at this, but the question is: Is there
any way to accomplish the MCARD technique without actually
instituting cardiopulmonary bypass, such as through a blood
recirculation technique?
In regard to your data in the current technique, my second
question, which was in your report, is even though you have
effectively shown much higher levels of cardiac uptake compared
to the liver, you did still have NAbs in your controls. Do you have
any further plans to improve isolation or address this issue?
Finally, recognizing that time did not allow your addressing this
issue, we know the retrograde perfusion technique preferentially de-
livers to the left ventricle andbypasses the right ventricle and septum.
Your expression with MCARD, I believe, has been heterogeneous
because of this. Are there any approaches that you could add to
your technique to improve right ventricular and septal delivery?
Again, congratulations on this very nice work.
Dr Bridges.Well, thanks, Todd, it is certainly a pleasure and an
honor to have our report reviewed by one of the pioneers in cardiac
gene therapy. Dr Rosengart conducted the first clinical trial of gene
therapy using cardiac surgery as a delivery platform more than a
decade ago. So, thank you for the opportunity to discuss this
with you.
Your first question was: Molecular cardiac surgery with
recirculating delivery, can it be done without cardiopulmonary
bypass? And that has been tried. I published a letter to the editor
in Gene Therapy in 2009 in which a ‘‘recirculating’’ delivery
technique known as ‘‘V-Focus’’ was reported that purported to
isolate the heart in situ. In fact, they actually did use a perfusion
circuit, so even that was not without cardiopulmonary bypass.
However, owing to the complexities of the cardiac circulation
with the Thebesian veins, for example, and in the sheep model
with the hemizygous vein, it is really difficult, if not impossible,
to effectively isolate the heart without cardiopulmonary bypass,
at least at present. Of course, that remains an open question. We
have developed some technology that should allow us to do it
minimally invasively, but at present, to achieve the 99%
efficacious separation of the 2 circuits requires cardiopulmonary
bypass. However, we are certainly interested in pursuing other
options, which might not be perfect but would enhance the
effectiveness of catheter-based delivery.
Your second question was the NAbs. We did, in fact, see
evidence of NAbs in our experimental group despite our 99%
efficient separation of the cardiac from the systemic circulation.
We published a report in the Journal of Cardiac Failure in 2011,
which was a pharmacokinetic analysis. The concern is patients
who have NAbs before you administer the gene therapy, which
decreases the efficacy of the gene delivery. If a patient develops
NAbs after gene delivery, it might or might not have an effect on
subsequent treatment but will not affect the efficacy of the therapy.
However, with most of these gene therapy protocols, one-time
treatment is really what we expect is likely to be efficacious, so
hopefully that will not be an important limitation. Apparently,
even the small amounts of antibody of the viral vector that moved
into the circulation with our technique, which, again, was orders of
magnitude less than with the intracoronary approach, was enough
to provoke a NAb.gery c September 2014
Katz et al Evolving Technology/Basic ScienceFinally, your question was about retrograde versus antegrade.
As you know, retrograde delivery more effectively transduces or
provides nutrient flow using retrograde cardioplegia to the left
ventricle and is less efficient in the right ventricle; and, in fact,
that is what we have seen in our work, in our previously published
work, as recently as a report published in August 2013 in the
Annals of Thoracic Surgery. However, although we have seen bet-The Journal of Thoracic and Carter transduction of the left ventricle than the right ventricle, we
have seen at least 10 to 100 times better transduction of even the
right ventricle using this technique than with the intracoronary de-
livery method. Thus, hopefully, that will still be enough to achieve
efficacy on the right side. Also, you could combine retrograde with
antegrade. Thus, a number of potential strategies exist that might
allow us to overcome that.diovascular Surgery c Volume 148, Number 3 1073
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TABLE E1. Complete blood count and blood chemistry summary
Variable
Reference
range Baseline
12-wk
point
Complete blood count
Hemoglobin (g/dL) 9-15 12.2  0.5 8.4  0.6
Total WBC (103/mL) 4-12 9.0  0.7 9.0  0.7
Total RBC (106/mL) 9.0-15.8 11.4  0.4 8.4  0.6
Hematocrit (%) 27-45 33.0  1.2 24.7  1.5
Platelet count (103/mL) 100-800 430  71 415  61
Neutrophils (%) 10-50 30.8  2.3 35.2  4.7
Lymphocytes (%) 40-75 64.2  3.1 63.8  4.9
Renal system
Urea nitrogen (mg/dL) 10-35 14.0  1.2 13.4  1.7
Sodium (mEq/L) 145-152 146.5  1.1 141.4  0.8
Potassium (mEq/L) 3.4-5.5 5.5  0.3 4.7  0.1
Creatinine (mg/dL) 0.2-1.9 0.70  0.06 0.64  0.08
Gastrointestinal system
Liver function
Alanine aminotransferase
(U/L)
22-38 16.2  1.4 29.0  5.2
Alkaline phosphatase (U/L) 70-390 180  27 76  11
Total bilirubin (mg/dL) 0.1-0.5 0.18  0.03 0.34  0.05
Albumin (g/dL) 2.4-4.0 3.17  0.08 2.21  0.15
Pancreatic function
Lipase (U/L) 5-35 15.0  2.3 10.0  8.0
Amylase (U/L) 22-35 13.2  2.5 10.7  1.4
Glucose (mg/dL) 50-80 62.3  3.5 74.0  3.1
Complete blood count
Hemoglobin (g/L) 90-150 122  5 84  6
Total WBC (109/L) 4-12 9.0  0.7 9.0  0.7
Total RBC (1012/L) 9.0-15.8 11.4  0.4 8.4  0.6
Hematocrit 0.27-0.45 0.33  0.01 0.25  0.01
Platelet count (109/L) 100-800 430  71 415  61
Neutrophils (109/L) 0.7-6.0 4.0  0.5 2.8  0.3
Lymphocytes (109/L) 2-9 4.5  0.6 6.1  0.6
Renal system
Urea nitrogen (mmol/L) 3.6-12.5 5.0  0.4 4.8  0.6
Creatinine (mmol/L) 18-168 62  5 56  7
Sodium (mmol/L) 145-152 146.5  1.1 141.4  0.8
Potassium (mmol/L) 3.4-5.5 5.5  0.3 4.7  0.1
Gastrointestinal system
Liver function
Alanine aminotransferase
(U/L)
22-38 16.2  1.4 29.0  5.2
Alkaline phosphatase (U/L) 70-390 180  27 76  11
Total bilirubin (mmol/L) 1.7-8.6 3.2  0.5 5.8  0.8
Albumin (g/L) 24-40 31.7  0.8 22.1  1.5
Pancreatic function
Lipase (U/L) 5-35 15.0  2.3 10.0  8.0
Amylase (U/L) 22-35 13.2  2.5 10.7  1.4
Glucose (mmol/L) 2.8-4.4 3.5  0.2 4.1  0.2
WBC, White blood cell; RBC, red blood cell.
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TABLE E2. Electrocardiographic segment analysis summary
ECG wave interval Baseline After acute MI
12-wk follow-up point
MCARD-SERCA2a Control (no treatment)
PQ interval (ms) 124  8 136  10 133  17 126  16
QRS interval (ms) 32  4 21  7 34  4 60  15
QT interval (ms) 305  23 343  25 339  37 348  17
ST deviation (mV) 37.5  14 346  80 33  17 27  10
Heart rate (beats/min) 113  13 103  17 100  16 96  7
ECG, Electrocardiographic; MI, myocardial infarction; MCARD-SERCA2a, molecular cardiac surgery with recirculating delivery of sarcoplasmic reticulum Ca2þ adenosine
triphosphatase.
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